ArticleFrontiers in antibiotics2026
The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring.
Article in Frontiers in antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is a global health challenge and is curable, but tools for rapid treatment monitoring are limited. Current methods, like smear microscopy, lack sensitivity, while culture-based approaches require weeks for results and specialized biosafety facilities. This paper presents a comprehensive protocol for the PATHFAST TB LAM Ag assay, a rapid chemiluminescent enzyme immunoassay that quantifies lipoarabinomannan (LAM) mainly in sputum and likely other biological samples within one hour. This protocol details sample collection, heat inactivation for biosafety, and the automated measurement process. Heat inactivation at 100 °C for 20 minutes renders samples non-infectious while preserving LAM for detection. The assay demonstrates excellent analytical performance with a detection limit of 6.67 pg/mL and a linear measurement range of 10.0-50,000 pg/mL. Published clinical evaluation demonstrated 88.8% (95% CI: 80.0-94.0%) sensitivity and 100% (95% CI: 83.9-100%) specificity compared to culture, with strong correlation to bacterial load. The PATHFAST TB LAM Ag assay successfully tracks bacterial decline during treatment, with LAM concentration reductions mirroring culture results but available significantly faster. Unlike culture methods that suffer from contamination (4.2-9.6% invalid results), the PATHFAST TB LAM Ag assay consistently provides valid results. This protocol enables implementation of a rapid, quantitative TB treatment monitoring tool that enhances biosafety, reduces turnaround time, and maintains performance comparable to conventional methods, addressing critical needs in both clinical care and drug development settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.